Drugging the Undruggable: Advances on RAS Targeting in Cancer

Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina-Arcas, Miriam, Samani, Amit, Downward, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228461/
https://www.ncbi.nlm.nih.gov/pubmed/34200676
http://dx.doi.org/10.3390/genes12060899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228461/
https://www.ncbi.nlm.nih.gov/pubmed/34200676
http://dx.doi.org/10.3390/genes12060899

Ejemplares similares